
A bright future for advanced therapies
2025 was a difficult year for cell and gene therapies (CGTs), as multiple companies discontinued their cell therapy efforts, including Galapagos, Novo Nordisk and Takeda, despite significant financial losses as a result. The complexity and expense of manufacturing the treatments has meant that even when they are approved, the therapies do not always reach the relevant patients. This,… Read More













